Stellar populations -- the next ten years

The study of stellar populations is a discipline that is highly dependent on both imaging and spectroscopy. I discuss techniques in different regimes of resolving power: broadband imaging (R~4), intermediate band imaging (R~16, 64), narrowband spectral imaging (R~256, 1024, 4096). In recent years, we have seen major advances in broadband all-sky surveys that are set to continue across optical and IR bands, with the added benefit of the time domain, higher sensitivity, and improved photometric accuracy. Tunable filters and integral field spectrographs are poised to make further inroads into intermediate and narrowband imaging studies of stellar populations. Further advances will come from AO-assisted imaging and imaging spectroscopy, although photometric accuracy will be challenging. Integral field spectroscopy will continue to have a major impact on future stellar population studies, extending into the near infrared once the OH suppression problem is finally resolved. A sky rendered dark will allow a host of new ideas to be explored, and old ideas to be revisited.Comment: Invited review, IAUS 241, "Stellar Populations as Building Blocks of Galaxies," eds. Vazdekis, Peletier. 12 pages, 1 table. (The sideways table should print ok; there are 10 columns.

Translating Glutamate: From Pathophysiology to Treatment

The neurotransmitter glutamate is the primary excitatory neurotransmitter in mammalian brain and is responsible for most corticocortical and corticofugal neurotransmission. Disturbances in glutamatergic function have been implicated in the pathophysiology of several neuropsychiatric disorders—including schizophrenia, drug abuse and addiction, autism, and depression—that were until recently poorly understood. Nevertheless, improvements in basic information regarding these disorders have yet to translate into Food and Drug Administration–approved treatments. Barriers to translation include the need not only for improved compounds but also for improved biomarkers sensitive to both structural and functional target engagement and for improved translational models. Overcoming these barriers will require unique collaborative arrangements between pharma, government, and academia. Here, we review a recent Institute of Medicine–sponsored meeting, highlighting advances in glutamatergic theories of neuropsychiatric illness as well as remaining barriers to treatment development.National Institute of Mental Health (U.S.) (grant R37MH49334)National Institute of Mental Health (U.S.) (Intramural Research Program)National Institute of Mental Health (U.S.) (R01DA03383)National Institute of Mental Health (U.S.) (P50MH086385)National Institutes of Health (U.S.)FRAXA Research FoundationHoward Hughes Medical InstituteSimons Foundatio